Short­ly af­ter its lat­est mega-round, Sir­naomics CEO Patrick Lu says it's time to go pub­lic

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter briefly putting off an IPO to pull in a $105 mil­lion Se­ries E round ear­li­er this month, Sir­naomics has filed for a Hong Kong pub­lic de­but.

CEO Patrick Lu is plan­ning on us­ing about half the pro­ceeds to de­vel­op and (if all goes well) com­mer­cial­ize one of the com­pa­ny’s lead small in­ter­fer­ing RNA (siR­NA) can­di­dates, STP705. Back in De­cem­ber, Sir­naomics said the can­di­date helped clear tu­mor cells in pa­tients with squa­mous cell skin can­cer in a Phase IIa tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER